source
- Biopharma layoffs must double in second half of 2026 to match 2025 cutsThe first half of 2026 saw biopharma companies cut slightly fewer jobs than the same period a year earlier, with layoffs affecting about 2% fewer employees overall. To reach the total workforce re…
- Roche halts lupus T-cell engager RG6382 development after early trial reviewRoche announced it is stopping work on RG6382, a bispecific T-cell engager targeting CD19 and CD3, which was being tested in a phase‑1 study in patients with systemic lupus erythematosus (SLE). Th…